INT39301

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 1986
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 50
Total Number 50
Disease Relevance 27.06
Pain Relevance 8.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Chd7) helicase activity (Chd7) DNA binding (Chd7)
Anatomy Link Frequency
liver 4
lung 4
blood 1
hepatocyte 1
muscles 1
Chd7 (Mus musculus)
Pain Link Frequency Relevance Heat
aspirin 832 100.00 Very High Very High Very High
dexamethasone 11 99.76 Very High Very High Very High
Inflammation 606 99.20 Very High Very High Very High
Paracetamol 68 98.94 Very High Very High Very High
Inflammatory stimuli 20 98.16 Very High Very High Very High
cytokine 101 97.04 Very High Very High Very High
fibrosis 39 94.88 High High
anesthesia 1 93.24 High High
rheumatoid arthritis 39 85.12 High High
chemokine 113 83.04 Quite High
Disease Link Frequency Relevance Heat
Rickettsiaceae Infection 172 100.00 Very High Very High Very High
Targeted Disruption 253 99.98 Very High Very High Very High
Stress 262 99.84 Very High Very High Very High
Anaemia 232 99.80 Very High Very High Very High
Adult Respiratory Distress Syndrome 88 99.64 Very High Very High Very High
Lung Injury 84 99.44 Very High Very High Very High
Injury 196 99.32 Very High Very High Very High
Hypersensitivity 100 99.28 Very High Very High Very High
INFLAMMATION 585 99.20 Very High Very High Very High
Disease 216 99.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The current position of LDA in secondary prevention in cardio- and cerebrovascular disease mean that it is unlikely that in future, trials will be run with LDA compared to placebo, but there might be opportunities in studies in primary prevention (as in the ASPREE trial in progress [28]) or where LDA is used for other conditions.


Gene_expression (used) of LDA associated with cerebrovascular disease and aspirin
1) Confidence 0.26 Published 2010 Journal BMC Geriatr Section Body Doc Link PMC2956719 Disease Relevance 0.62 Pain Relevance 0.34
Study details and results are shown in Additional file 4 (Additional file 4: Prevalence data: LDA use in various settings).
Gene_expression (use) of LDA associated with aspirin
2) Confidence 0.23 Published 2010 Journal BMC Geriatr Section Body Doc Link PMC2956719 Disease Relevance 0.48 Pain Relevance 0.30
Conditions where LDA prescription may be appropriate are common in older people and many clinicians will recognize the common scenario of having to decide on prescribing LDA for secondary prevention in a mildly anemic elderly patient.
Gene_expression (prescription) of LDA associated with aspirin
3) Confidence 0.23 Published 2010 Journal BMC Geriatr Section Body Doc Link PMC2956719 Disease Relevance 0.37 Pain Relevance 0.40
The current position of LDA in secondary prevention in cardio- and cerebrovascular disease mean that it is unlikely that in future, trials will be run with LDA compared to placebo, but there might be opportunities in studies in primary prevention (as in the ASPREE trial in progress [28]) or where LDA is used for other conditions.


Gene_expression (used) of LDA associated with cerebrovascular disease and aspirin
4) Confidence 0.23 Published 2010 Journal BMC Geriatr Section Body Doc Link PMC2956719 Disease Relevance 0.54 Pain Relevance 0.31
We found data on prevalence of LDA prescribing and anemia (or Hb levels) in three studies in community settings [40-42], noted as patient characteristics in three studies of treatment of cardiovascular disease in older patients [43-45], and in four studies in secondary care in patients considered for investigation of anemia [46-49].
Gene_expression (prescribing) of LDA associated with aspirin, anaemia and cardiovascular disease
5) Confidence 0.23 Published 2010 Journal BMC Geriatr Section Body Doc Link PMC2956719 Disease Relevance 0.58 Pain Relevance 0.31
The prevalence of LDA prescription in a primary care population and the mean change in Hb over time (in the absence of overt bleeding) were observed [40].
Gene_expression (prescription) of LDA associated with aspirin and hemorrhage
6) Confidence 0.23 Published 2010 Journal BMC Geriatr Section Body Doc Link PMC2956719 Disease Relevance 0.47 Pain Relevance 0.30
While some studies indicated that Hb levels were reduced with LDA, others showed no change, or even suggested a higher Hb level.
Gene_expression (reduced) of LDA associated with aspirin
7) Confidence 0.23 Published 2010 Journal BMC Geriatr Section Body Doc Link PMC2956719 Disease Relevance 0.25 Pain Relevance 0.45
In both of these studies there was a statistically significant fall in Hb at one year compared with baseline in the LDA arms of the trials, but not in the placebo groups; there were also statistically significant differences in Hb between LDA and placebo groups at one year in both studies.
Gene_expression (arms) of LDA in arms associated with aspirin
8) Confidence 0.23 Published 2010 Journal BMC Geriatr Section Body Doc Link PMC2956719 Disease Relevance 0.29 Pain Relevance 0.21
These recommendations come at a time when both remission and LDA are achievable goals with the current therapeutic armamentarium.31 32 The recommendations are primarily meant to provide guidance on ways towards this goal, as seen by experts.
Gene_expression (remission) of LDA
9) Confidence 0.18 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3015099 Disease Relevance 0.49 Pain Relevance 0.13
The role of metallothionein (MT) in protecting the liver against paracetamol (PCT) toxicity was investigated in vivo and in vitro in mice lacking expression of MT-1 and MT-2 genes (MT -/-).
Gene_expression (expression) of MT in liver associated with toxicity and paracetamol
10) Confidence 0.15 Published 1998 Journal Toxicology Section Abstract Doc Link 9570328 Disease Relevance 0.34 Pain Relevance 0.44
On

the other hand, lung expression of MT is reportedly induced by O3 exposure in vivo [62, 63].

Gene_expression (expression) of MT in lung
11) Confidence 0.15 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2679981 Disease Relevance 1.09 Pain Relevance 0.20
targeted deletion or transgenic overexpression of MT genes.
Gene_expression (overexpression) of MT associated with targeted disruption
12) Confidence 0.15 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2679981 Disease Relevance 0.35 Pain Relevance 0
All four MT genes are expressed in the
Gene_expression (expressed) of MT
13) Confidence 0.15 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2679981 Disease Relevance 0.24 Pain Relevance 0.07
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities elevated by injection of Cd were significantly higher in the MT-I/II null mice than in the wild-type mice.
Gene_expression (higher) of MT
14) Confidence 0.15 Published 2010 Journal J Toxicol Sci Section Abstract Doc Link 20371971 Disease Relevance 0.40 Pain Relevance 0.13
To determine the effects of this drug-induced necrosis on cadmium (Cd) metabolism, mice were given a sublethal dose of CdCl2 . 2.5 H2O containing 109CdCl2 and maintained for a period of time sufficient for Cd-metallothionein (Cd-MT) to be synthesized and distributed.
Gene_expression (synthesized) of Cd-MT associated with necrosis
15) Confidence 0.14 Published 1986 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 3945963 Disease Relevance 0.27 Pain Relevance 0.47
that MT is protective against acute liver injury induced by LPS/D- GalN through
Gene_expression (protective) of MT in liver associated with injury
16) Confidence 0.13 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2679981 Disease Relevance 1.45 Pain Relevance 0.15
Pretreatment of mice with ACM 6 or 24 hr prior to Cd administration caused aberrations of the normal Cd distribution pattern, but no effect was noted when Cd administration was delayed for 48 hr after ACM injection, indicating recovery of the mechanisms of Cd-MT synthesis and sequestration.
Gene_expression (synthesis) of Cd-MT associated with paracetamol
17) Confidence 0.13 Published 1986 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 3945963 Disease Relevance 0.17 Pain Relevance 0.68
Generation of apo-MT with Dex may offer more protection than Zn-MT.
Gene_expression (Generation) of MT associated with dexamethasone
18) Confidence 0.12 Published 1998 Journal Toxicology Section Abstract Doc Link 9570328 Disease Relevance 0.44 Pain Relevance 0.82
Also, MT expression in various organs/tissues can be enhanced by inflammatory stimuli, implicating in inflammatory diseases.
Gene_expression (expression) of MT associated with inflammation, disease and inflammatory stimuli
19) Confidence 0.12 Published 2009 Journal Mediators of Inflammation Section Abstract Doc Link PMC2679981 Disease Relevance 0.93 Pain Relevance 0.23
MT expression is induced/enhanced in various tissues by a number of physiological mediators.
Gene_expression (expression) of MT
20) Confidence 0.12 Published 2009 Journal Mediators of Inflammation Section Abstract Doc Link PMC2679981 Disease Relevance 0.13 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox